IL13 and Alzheimer disease: Actually, dupilumab, an antibody against IL-4 receptor α, which can block both IL-4 and IL-13 signaling, significantly improved skin lesions and pruritus in patients with moderate to severe AD in two randomized, placebo-controlled clinical trials [6].